Rocuronium Bromide Injection, Solution
Product Images NDC 0409-3189

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Rocuronium Bromide (NDC 0409-3189). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hospira, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Rocuronium-spl-carton-100-mg (Rocuronium Spl Carton 100 mg)

Packaging label for Rocuronium Bromide Injection, 100 mg/10 mL (10 mg/mL) by Hospira, Inc. The label indicates multiple dose vials, contains 10 vials per package, and is for intravenous use only. The label includes warnings that Rocuronium Bromide is a paralyzing agent and requires facilities for artificial respiration. Storage instructions specify refrigeration between 2 to 8C, do not freeze, and usage timelines after removal or opening. The product is made in India and distributed by Hospira, Inc.*

FDA Label Image

Rocuronium-spl-carton-50-mg (Rocuronium Spl Carton 50 mg)

Packaging label for rocuronium bromide injection, 10 mg/mL (50 mg/5 mL) in solution form for intravenous use. The label includes warnings about paralytic effects and storage instructions to keep refrigerated. It is a multiple dose vial pack of 10 x 5 mL and is distributed by Hospira, Inc. The packaging states that the product is sterile and nonpyrogenic with no natural rubber latex in packaging.*

FDA Label Image

Rocuronium-spl-fig-1 (Rocuronium Spl Fig 1)

A scatter and box plot chart showing the distribution of rocuronium bromide injection times in minutes across different dosages (0.45, 0.9, 1.2 mg/kg) and age groups (18-64 years, 65 years and older, 1-12 years). The chart illustrates variability and median values for onset times by dose and age.*

FDA Label Image

Rocuronium-spl-fig-2 (Rocuronium Spl Fig 2)

A scatter plot with box plots showing data on a time variable measured in minutes across different age and dosage groups, ranging from ages 18-64 years, 65 years and older, to pediatric ages 3 months to 1 year and 1 to 12 years, with doses indicated in mg/kg. The chart likely illustrates variability or distribution of time measurements in these groups.*

FDA Label Image

Rocuronium-spl-fig-3 (Rocuronium Spl Fig 3)

A line graph depicting the relationship between dose number (1 to 5) on the x-axis and time in minutes (0 to 30) on the y-axis. Two lines represent different dose levels: 0.1 mg/kg and 0.15 mg/kg, with sample sizes of 29 and 13, respectively.*

FDA Label Image

Rocuronium-spl-fig-4 (Rocuronium Spl Fig 4)

FDA Label Image

Rocuronium-spl-structure (Rocuronium Spl Structure)

Chemical structure of rocuronium bromide, showing its steroid-like core with multiple rings, functional groups, and a bromide ion.*

FDA Label Image

Rocuronium-spl-vial-100-mg (Rocuronium Spl Vial 100 mg)

Label for Rocuronium Bromide Injection 100 mg/10 mL (10 mg/mL) solution in a 10 mL multiple dose vial. The label includes warnings that it is a paralyzing agent for intravenous use only and is distributed by Hospira, Inc. Storage instructions specify refrigeration between 2 to 8°C and to avoid freezing.*

FDA Label Image

Rocuronium-spl-vial-50-mg (Rocuronium Spl Vial 50 mg)

Label for Rocuronium Bromide Injection 50 mg/5 mL (10 mg/mL) in a 5 mL multiple dose vial. The label includes warnings that the product is a paralyzing agent causing respiratory arrest and is for intravenous use only. Storage instructions specify refrigeration between 2 to 8°C, no freezing, and stability information after removal from refrigeration. Distributed by Hospira, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.